You searched for Vaccines - Page 55 of 55

News and Trends 12 Mar 2015

Sanofi and its Succesful Pivot from Chemistry to Biotechnology [BIO-Spring 2015]

Sanofi is France’s largest pharma company and the 3rd biggest in the World. The VIP guest of BIO-Europe Spring was Serge Weinberg, Chairman and temporary CEO of Sanofi. You might have been expecting a boring corporate conference with a strong Frenchy-accent English but actually, the talk was extremely clear and interesting. Weinberg went through Sanofi’s innovation strategy as […]

March 12, 2015 - 4 minutesmins - By Philip Hemme

News and Trends 5 Mar 2015

Novartis announces completion of transactions with GSK

Completes transactions with GSK including: acquisition of GSK oncology portfolio, creation of Consumer Healthcare joint venture, and sale of non-influenza Vaccines business Sharpens company focus on growing segments of innovative pharmaceuticals, eye care and generics Addition of GSK oncology products and two pipeline compounds is expected to expand Novartis position in targeted therapies and small […]

March 5, 2015 - 5 minutesmins - By Cédric Brock

News and Trends 3 Mar 2015

Calixar Raises €1 Million to License-out its Isolation Technologies

CALIXAR, develops new approaches to isolate in solution – with the highest purity levels – full-length membrane antigens and proteins, whilst keeping their structural and functional integrity. The company announced the completion of its second round of financing with its historical investors, Bpifrance (French public investment bank) and the Banque Populaire. The aim of this […]

March 3, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 27 Feb 2015

Sanofi: Get Ready for the Launch of the First Inhaled Insulin in the U.S.

Sanofi, the global healthcare leader has core strengths in the field of healthcare due to its seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. This article will focus on Sanofi Diabetes. In August 2014, our previous article “Sanofi buys Mannkind’s inhaled insulin for €824.5m” […]

February 27, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 26 Feb 2015

SSB’s Ambr Bioreactor Systems Enhanced with Software for Design of Experiments

The French company, Sartorius Stedim Biotech (SSB), announced that the 2015 version of the Ambr systems (Ambr 15 and Ambr 250) will be supplied with integrated BioPAT MODDE Software for Design of Experiments (DoE), powered by Umetrics. This will allow bioprocess scientists to easily implement DoE into their work flow for simpler process optimization and […]

February 26, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 22 Feb 2015

Theravectys: an Orphan Drug Designation for Its Lentiviral Vector-Based Therapeutic Vaccine

THERAVECTYS, a fully-integrated discovery and clinical development biotechnology company focusing on the development of therapeutic vaccines and immunotherapy, announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to its therapeutic vaccine candidate for the treatment of Adult T-cell Leukemia/Lymphoma (ATL/L). ATL/L is a rare malignancy of a certain type of white cells, T-Lymphocytes, caused by the Human T-Cell Lymphotropic Virus type […]

February 22, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 7 Dec 2014

Ebola, the fever falls

This article provides an update of the 2014 Ebola outbreak relating to other past outbreaks of this disease. It provides demographic and economic insights into both the disease and the regions affected. It highlights lessons learnt and those that need to be learned. Which sectors are most impacted by this outbreak, and what is the […]

December 7, 2014 - 15 minutesmins - By Cédric Brock

News and Trends 3 Dec 2014

New Technologies Against Allergies are on the Wave

Anergis, a company developing proprietary ultra-fast allergy vaccines, closed a Series B financing round totaling 12,1 million euros. Anergis is not the only company that focuses on allergies, DBV technologies also recently raised money for its new anti-allergic patch. Allergies are the most prevalent and fastest growing chronic conditions in the industrialized world affecting over 500 million […]

December 3, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 2 Dec 2014

Red biotechnology is not restricted to humans

The relevance of biotechnology is certainly not restricted to the human domain, and rightly so, because over the ages humans have always been around animals and even more presently when the ratio of pets per inhabitants increase every year. The food industry and veterinary medicine are constantly trying to improve their traits creating new races, […]

December 2, 2014 - 6 minutesmins - By Cédric Brock

News and Trends 30 Oct 2014

Review : Ebola, The True Story

The first outbreaks of Ebola (also known as Ebola haemorrhagic fever) have occurred in isolated villages in central Africa, near tropical forests, but the recent outbreak in West Africa has affected major urban centers as well as rural areas. The Ebola virus disease shows an average fatality rate about 50%. In previous outbreaks, the rate […]

October 30, 2014 - 26 minutesmins - By Cédric Brock

News and Trends 11 Oct 2014

ARTES Biotechnology, instrAction and Q-Biologicals Join Forces for Veterinary Vaccine Development

ARTES Biotechnology, InstrAction and Q-Biologicals establish a three-party consortium for vaccine developments for veterinary applications. Nowadays virus-like particles (VLPs) have become a widely used vehicle for the development of vaccines used in humans. Without being infectious, the particles are used to transport foreign antigens in an ideal way to the immune system. For veterinary applications, the applied VLP production […]

October 11, 2014 - 3 minutesmins - By Julie Lellouche

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us